U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula Fe.2I
Molecular Weight 309.654
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FERROUS IODIDE

SMILES

[Fe++].[I-].[I-]

InChI

InChIKey=BQZGVMWPHXIKEQ-UHFFFAOYSA-L
InChI=1S/Fe.2HI/h;2*1H/q+2;;/p-2

HIDE SMILES / InChI
Molecular Formula Fe
Molecular Weight 55.845
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula HI
Molecular Weight 127.91241
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/3541174 | https://books.google.ru/books?id=7mxyBgAAQBAJ&pg=PA13&lpg=PA13&dq=%22ferrous+iodide%22+anemia&source=bl&ots=ZGyFhUiJZ4&sig=IZOhRVaGmlwX7GcqgoE6rnCsCa4&hl=ru&sa=X&ved=0ahUKEwjYu7PCyYHUAhWiQpoKHR6cCfcQ6AEIUjAJ#v=onepage&q=%22ferrous%20iodide%22&f=false

There is no information about biological and pharmacological application of Iron(II) fluoride (also known as ferrous fluoride). It is known, that this substance is used to catalyze some organic reactions.

Originator

Approval Year

1921
1468
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Not Provided
511
Unknown

Approved Use

Unknown
Palliative
Not Provided
511
Unknown

Approved Use

Unknown
Primary
Approved
8583
Ferro Sanol Duodenal

Approved Use

Ferro Sanol is an iron substitute in case of latent or manifest iron deficiency with and without development of anaemia.
Curative
Approved
8583
RADIOGARDASE

Approved Use

Insoluble Prussian blue is indicated for treatment of patients with known or suspected internal contamination with radioactive cesium and/or radioactive or non-radioactive thallium to increase their rates of elimination.

Launch Date

2003
PubMed

PubMed

TitleDatePubMed
THE USE OF FERROUS GLUCONATE IN THE TREATMENT OF HYPOCHROMIC ANEMIA.
1937 Jul
Clinical appraisal of drugs with special reference to a new chelate hematinic.
1957 Jul 11
The effect of iron treatment on adhesion molecules in patients with iron deficiency anemia.
2010 Dec
A practical and successful desensitization protocol for immediate hypersensitivity reactions to iron salts.
2014
Patents

Patents

CN105565963
37
US20020127665
37
US2009028810
37
US20150202224
37
US2877253
37
US3091626
37
US5534268
37
US6407138
37
US8080520
37
US8802114
37

Sample Use Guides

In Vivo Use Guide
Adults should usually take one capsule a day. In cases of pronounced iron deficiency, adults can be given a dosage 2 to 3 times higher at the beginning of therapy. A daily dose of more than 5 mg Fe2+/kg body weight should in-well founded exceptional cases not be exceeded.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:16:28 GMT 2025
Edited
by admin
on Mon Mar 31 18:16:28 GMT 2025
Record UNII
F5452U54PN
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FERROUS IODIDE
MI  
Common Name English
FERRUM IODATUM
HPUS  
Preferred Name English
FERROUS IODIDE [MI]
Common Name English
FERRUM IODATUM [HPUS]
Common Name English
IRON(II) IODIDE
Systematic Name English
IRON DIIODIDE
Systematic Name English
Ferrous iodide [WHO-DD]
Common Name English
Classification Tree Code System Code
WHO-VATC QB03AA11
Created by admin on Mon Mar 31 18:16:28 GMT 2025 , Edited by admin on Mon Mar 31 18:16:28 GMT 2025
WHO-ATC B03AA11
Created by admin on Mon Mar 31 18:16:28 GMT 2025 , Edited by admin on Mon Mar 31 18:16:28 GMT 2025
Code System Code Type Description
CAS
7783-86-0
Created by admin on Mon Mar 31 18:16:28 GMT 2025 , Edited by admin on Mon Mar 31 18:16:28 GMT 2025
PRIMARY
NCI_THESAURUS
C87333
Created by admin on Mon Mar 31 18:16:28 GMT 2025 , Edited by admin on Mon Mar 31 18:16:28 GMT 2025
PRIMARY
DAILYMED
F5452U54PN
Created by admin on Mon Mar 31 18:16:28 GMT 2025 , Edited by admin on Mon Mar 31 18:16:28 GMT 2025
PRIMARY
PUBCHEM
82220
Created by admin on Mon Mar 31 18:16:28 GMT 2025 , Edited by admin on Mon Mar 31 18:16:28 GMT 2025
PRIMARY
RXCUI
1311296
Created by admin on Mon Mar 31 18:16:28 GMT 2025 , Edited by admin on Mon Mar 31 18:16:28 GMT 2025
PRIMARY RxNorm
MERCK INDEX
m5346
Created by admin on Mon Mar 31 18:16:28 GMT 2025 , Edited by admin on Mon Mar 31 18:16:28 GMT 2025
PRIMARY Merck Index
WIKIPEDIA
Iron(II) iodide
Created by admin on Mon Mar 31 18:16:28 GMT 2025 , Edited by admin on Mon Mar 31 18:16:28 GMT 2025
PRIMARY
EVMPD
SUB89573
Created by admin on Mon Mar 31 18:16:28 GMT 2025 , Edited by admin on Mon Mar 31 18:16:28 GMT 2025
PRIMARY
FDA UNII
F5452U54PN
Created by admin on Mon Mar 31 18:16:28 GMT 2025 , Edited by admin on Mon Mar 31 18:16:28 GMT 2025
PRIMARY
SMS_ID
100000140199
Created by admin on Mon Mar 31 18:16:28 GMT 2025 , Edited by admin on Mon Mar 31 18:16:28 GMT 2025
PRIMARY
EPA CompTox
DTXSID301014473
Created by admin on Mon Mar 31 18:16:28 GMT 2025 , Edited by admin on Mon Mar 31 18:16:28 GMT 2025
PRIMARY
NCI_THESAURUS
C1505
Created by admin on Mon Mar 31 18:16:28 GMT 2025 , Edited by admin on Mon Mar 31 18:16:28 GMT 2025
CONCEPT Dietary Supplement
ECHA (EC/EINECS)
232-031-2
Created by admin on Mon Mar 31 18:16:28 GMT 2025 , Edited by admin on Mon Mar 31 18:16:28 GMT 2025
PRIMARY
Related Record Type Details
Structure of FERROUS CATION
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of FERROUS IODIDE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966